Guidance

MenACWY vaccine (Menveo® or Nimenrix®): patient group direction (PGD) template

PGD template to support the national Meningococcal group A,C,W and Y (Menveo® or Nimenrix®) vaccination programme.

Documents

Meningococcal group A,C,W and Y vaccine (Menveo® or Nimenrix®) PGD template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of meningococcal group A, C, W and Y conjugate vaccine (MenACWY) to individuals eligible for national routine MenACWY vaccination programme and university freshers (catch-up) programme. It also covers administration of MenACWY vaccine for outbreak control and contacts of confirmed cases, in accordance with the guidance for the public health management of meningococcal disease in the UK.

The MenACWY PGD V03.00 is valid from 1 July 2019 to 31 July 2021.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics.

Published 14 July 2015
Last updated 4 June 2019 + show all updates
  1. Added version V03.00 following routine review of PGD prior to expiry.
  2. Added revised PGD v02.00 to replace expiring v01.00 from 1 July 2017
  3. First published.